Cargando…
Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
Abnormality in glucose homeostasis due to hyperglycemia or insulin resistance is the hallmark of type 2 diabetes mellitus (T2DM). These metabolic abnormalities in T2DM lead to cellular dysfunction and the development of diabetic cardiomyopathy leading to heart failure. New antihyperglycemic agents i...
Autores principales: | Al-Shamasi, Al-Anood, Elkaffash, Rozina, Mohamed, Meram, Rayan, Menatallah, Al-Khater, Dhabya, Gadeau, Alain-Pierre, Ahmed, Rashid, Hasan, Anwarul, Eldassouki, Hussein, Yalcin, Huseyin Cagatay, Abdul-Ghani, Muhammad, Mraiche, Fatima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657861/ https://www.ncbi.nlm.nih.gov/pubmed/34884494 http://dx.doi.org/10.3390/ijms222312677 |
Ejemplares similares
-
Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression
por: Abdulrahman, Nabeel, et al.
Publicado: (2022) -
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study
por: Moustafa, Diala Alhaj, et al.
Publicado: (2022) -
Osteopontin: A Promising Therapeutic Target in Cardiac Fibrosis
por: Abdelaziz Mohamed, Iman, et al.
Publicado: (2019) -
Iodide Binding in Sodium-Coupled Cotransporters
por: Vergara-Jaque, Ariela, et al.
Publicado: (2017) -
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)